Clinical Trial Update: Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) [Phase 2]

View source ↗

Summary

A phase 2 MATCH subprotocol M trial update evaluating MLN0128 (TAK-228) as a targeted treatment for cancers with TSC1 or TSC2 genetic changes. The study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumor

Drugs mentioned

• MLN0128 (TAK-228) (MLN0128)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING